PolyPeptide Shareholders Approve Board Overhaul and Removal of Transfer Restrictions Ahead of Samsung Biologics Takeover
PolyPeptide Group AG, a specialized global contract development and manufacturing organization for peptide-based active pharmaceutical ingredients, announced that its shareholders…
TR
By Tom Reyes · Markets Editor
Oct 27 01:30 ETSource: citybuzz -
From the source
Read at citybuzz.coPolyPeptide Shareholders Approve Board Overhaul and Removal of Transfer Restrictions Ahead of Samsung Biologics Takeover
PolyPeptide Group AG, a specialized global contract development and manufacturing organization for peptide-based active pharmaceutical ingredients, announced that its shareholders approved all proposals put forward by the board of directors at an extraordinary general meeting held on October 26, 2026. The approvals mark a significant step toward the completion of a public tender offer by Samsung P
